IMU Biosciences
Agent42Agent Readiness: 42/100. Above median. Measured by StartupHub.ai. Median 41.Trust83Data Trust: 83/100. Top 25%. Measured by StartupHub.ai. Median 61.Decoding the immune system to pioneer a paradigm shift in disease diagnosis and treatment.
About
IMU Biosciences is a biotechnology company developing "HD Immunology" by decoding the immune system with unprecedented resolution and scale. Their core offering is a multi-omic platform that generates over 100 million immune data points from 2ml of blood, resolving 2,500 discrete immune cell subsets in real-time to build the world's largest immune dataset. This platform powers precision medicine initiatives, including predictive screening tools for Hematopoietic Stem Cell Transplantation and graft rejection in Solid Organ Transplantation.
Similar companies
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Biotech
Biotechnology company focused on cellular rejuvenation to reverse disease and extend healthspan.
Shares Biotechnology, HealthTech
A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
Shares Biotechnology, Genomics
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Biotech
Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.
Shares Biotechnology, Artificial Intelligence
Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
Shares Biotechnology, Artificial Intelligence
Key facts
- Website
- imubiosciences.com
- Headquarters
- London, England, United Kingdom
- Total funding
- $53M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 2 Jun 2026 | Series A | $53M | IQ Capital, Molten Ventures |
Tech stack
Detected on imubiosciences.com, last scanned 30 Oct 2026. Run your own scan
- Analytics
- Google Analytics 4
- CMS / Builders
- Framer
- Email provider
- Google Workspace
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
Is IMU Biosciences trustworthy and reputable?
StartupHub's Data Trust & Reputation score for IMU Biosciences is 83 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has IMU Biosciences raised?
IMU Biosciences has raised a total of $53M in funding. The most recent round on record is Series A.
SEC filings, insider activity, nonprofit links and pay benchmarks for IMU Biosciences:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
